← Back to patent-cliff list
ARO-C3
Tier C — Watch / tradeARO-C3
Arrowhead Pharmaceuticals Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Nucleic acid drug
Type
Targets：C3
Indications (approved)：C3肾小球病, 免疫球蛋白a肾病
Regional status
US
-
EU
Phase II
2022-02-01
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of ARO-C3?
Approved indications include: C3肾小球病, 免疫球蛋白a肾病.
When does the ARO-C3 patent expire?
No public expiry year is available for ARO-C3 yet; this page updates once verified.
How do I get a quote for ARO-C3 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-05